109 related articles for article (PubMed ID: 29767438)
21. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
[TBL] [Abstract][Full Text] [Related]
22. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer.
Pang L; Wang J; Jiang Y; Chen L
Exp Ther Med; 2013 Aug; 6(2):355-360. PubMed ID: 24137188
[TBL] [Abstract][Full Text] [Related]
23. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
24. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
[TBL] [Abstract][Full Text] [Related]
25. [Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer].
Chen Y; Peng W; Huang Y; Chen J; Su G; Jiang C; Xiao Y
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):508-11. PubMed ID: 26463326
[TBL] [Abstract][Full Text] [Related]
26. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
27. Clinical risk factors of carbohydrate antigen-125, cytokeratin fragment 19, and neuron-specific enolase in liver metastases from elderly lung cancer patients.
Cheng T; Chen J; Ying P; Wei H; Shu H; Kang M; Zou J; Ling Q; Liao X; Wang Y; Shao Y
Front Genet; 2022; 13():1013253. PubMed ID: 36246602
[No Abstract] [Full Text] [Related]
28. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations.
Dong J; Tong S; Shi X; Wang C; Xiao X; Ji W; Sun Y
Cancer Manag Res; 2020; 12():13607-13616. PubMed ID: 33447080
[TBL] [Abstract][Full Text] [Related]
29. Serum carcinoembryonic antigen, neuron-specific enolase as biomarkers for diagnosis of nonsmall cell lung cancer.
Dong Y; Zheng X; Yang Z; Sun M; Zhang G; An X; Pan L; Zhang S
J Cancer Res Ther; 2016 Oct; 12(Supplement):34-36. PubMed ID: 27721249
[TBL] [Abstract][Full Text] [Related]
30. Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
He X; Zhang Y; Ma Y; Zhou T; Zhang J; Hong S; Sheng J; Zhang Z; Yang Y; Huang Y; Zhang L; Zhao H
Medicine (Baltimore); 2016 Aug; 95(31):e4176. PubMed ID: 27495021
[TBL] [Abstract][Full Text] [Related]
31. Reduction of Serum Cytokeratin-3A9 is Associated with Chemotherapeutic Response in Patients with Non-Small Cell Lung Cancer.
Shi GL; Wu ED; Sun Y; Yin YJ; Song CX
Clin Lab; 2015; 61(5-6):497-504. PubMed ID: 26118182
[TBL] [Abstract][Full Text] [Related]
32. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].
Gao J; Zhang L; Peng K; Sun H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):886-891. PubMed ID: 35790439
[TBL] [Abstract][Full Text] [Related]
33. Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer.
Ishiguro F; Fukui T; Mori S; Katayama T; Sakakura N; Hatooka S; Mitsudomi T
Ann Thorac Cardiovasc Surg; 2010 Aug; 16(4):242-7. PubMed ID: 21057440
[TBL] [Abstract][Full Text] [Related]
34. The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer.
Wu H; Wang Q; Liu Q; Zhang Q; Huang Q; Yu Z
Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162867
[TBL] [Abstract][Full Text] [Related]
35. CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.
Facchinetti F; Aldigeri R; Aloe R; Bortesi B; Ardizzoni A; Tiseo M
Tumour Biol; 2015 Aug; 36(8):5943-51. PubMed ID: 25731731
[TBL] [Abstract][Full Text] [Related]
36. Value of Growth/Differentiation Factor 15 in Diagnosis and the Evaluation of Chemotherapeutic Response in Lung Cancer.
Deng J; Zhang M; Zhang H; Lu C; Hou G; Feng Y; Fang Z; Lv X
Clin Ther; 2021 Apr; 43(4):747-759. PubMed ID: 33691944
[TBL] [Abstract][Full Text] [Related]
37. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
38. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
39. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
40. Methylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer.
Zhang Y; Huang J; Zou Q; Che J; Yang K; Fan Q; Qian D; Wu J; Bao E; Song L; Zhang F
Oncol Lett; 2020 Apr; 19(4):3229-3238. PubMed ID: 32256818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]